Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial-Reference-Cited by-同舟云学术

Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial

Published:2016-06 Issue:6 Volume:27 Page:1041-1047
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mackey J.R.,Pieńkowski T.,Crown J.,Sadeghi S.,Martin M.,Chan A.,Saleh M.,Sehdev S.,Provencher L.,Semiglazov V.,Press M.F.,Sauter G.,Lindsay M.,Houé V.,Buyse M.,Drevot P.,Hitier S.,Bensfia S.,Eiermann W.

Funder

Aventis

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/6/1041/16701408/mdw098.pdf

Reference13 articles.

1. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials;Peto;Lancet,2012

2. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27;Bear;J Clin Oncol,2006

3. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial;Roche;J Clin Oncol,2006